Schedule 13G ownership disclosure

BIOXCEL THERAPEUTICS INC

Common Stock, par value $0.001 per share · CUSIP: 09075P105

Event date: 2024-11-25

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Oaktree Fund Advisors, LLC

    Shares: 822,944 · Class: 1.6%

  • OAKTREE CAPITAL MANAGEMENT LP

    Shares: 1,901,131 · Class: 3.6%

  • Oaktree Capital Group Holdings GP, LLC

    Shares: 2,724,075 · Class: 5.2%

  • Oaktree Capital Holdings, LLC

    Shares: 2,724,075 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001140361-24-049871
Form type
SCHEDULE 13G
Filer
BioXcel Therapeutics, Inc.
CIK
CIK 1720893
Filed
Dec 18, 2024
Reporting period
Nov 25, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub